About D(3) dopamine receptor
D(3) dopamine receptor (DRD3) is a protein
from Homo sapiens identified by UniProt accession
P35462, 400 residues long.
MolForge cross-references it against 0 known binders and
278 disease associations.
Target properties
| Protein name | D(3) dopamine receptor |
|---|
| UniProt accession | P35462 |
|---|
| Gene | DRD3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 400 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (16)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (278)
Diseases linked to this target (Open Targets).
- schizophrenia · score 0.70
- Parkinson disease · score 0.61
- bipolar disorder · score 0.61
- schizoaffective disorder · score 0.60
- restless legs syndrome · score 0.60
- Agitation · score 0.60
- unipolar depression · score 0.59
- psychosis · score 0.59
- depressive disorder · score 0.59
- major depressive disorder · score 0.59
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P35462-F1 | alphafold | PREDICTED | 75.38 | — |
Amino-acid sequence (400 residues)
MASLSQLSGH LNYTCGAENS TGASQARPHA YYALSYCALI LAIVFGNGLV CMAVLKERAL QTTTNYLVVS LAVADLLVAT LVMPWVVYLE VTGGVWNFSR ICCDVFVTLD VMMCTASILN LCAISIDRYT AVVMPVHYQH GTGQSSCRRV ALMITAVWVL AFAVSCPLLF GFNTTGDPTV CSISNPDFVI YSSVVSFYLP FGVTVLVYAR IYVVLKQRRR KRILTRQNSQ CNSVRPGFPQ QTLSPDPAHL ELKRYYSICQ DTALGGPGFQ ERGGELKREE KTRNSLSPTI APKLSLEVRK LSNGRLSTSL KLGPLQPRGV PLREKKATQM VAIVLGAFIV CWLPFFLTHV LNTHCQTCHV SPELYSATTW LGYVNSALNP VIYTTFNIEF RKAFLKILSC
Explore D(3) dopamine receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets